This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Original Article -
Novel flutamide regulated genes in the rat ventral prostate:
differential modulation of their expression by castration and
flutamide treatments
Anil M. Limaye, Irfan Asangani, Namrata Bora, Paturu Kondaiah
Department of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore 560012, India
Abstract
Aim: To identify flutamide regulated genes in the rat ventral prostate.
Methods: Total RNA from ventral prostates of
control and flutamide treated rats were isolated. Differentially expressed transcripts were identified using differential
display reverse transcriptase polymerase chain reaction. The effect of castration on the expression of
flutamide-regulated transcripts was studied.
Results: We have identified β2-microglobulin, cytoplasmic FMR1 interacting
protein 2 and pumilio 1 as flutamide induced and spermine binding protein and ribophorin II as flutamide repressed
targets in the rat ventral prostate. Although flutamide treatment caused
an induction of pumilio 1 mRNA, castration had no
effect. Conclusion: Castration and flutamide treatments exert differential effects on gene expression. Flutamide
might also have direct AR independent effects, which might have implications in the emergence of androgen
independent prostate cancer and the failure of flutamide therapy.
(Asian J Androl 2007 Nov; 9: 801_808)
Keywords: androgens; antiandrogen; castration; differential display reverse transcriptase polymerase chain reaction; flutamide; prostate
Correspondence to: Dr Paturu Kondaiah, Department of Molecular Reproduction, Development and Genetics, Indian Institute of Science,
Bangalore 560012, India.
Tel: +91-080-2293-2688 Fax: +91-080-2360-0999
E-mail: paturu@mrdg.iisc.ernet.in
Received 2006-11-03 Accepted 2007-04-19
DOI: 10.1111/j.1745-7262.2007.00293.x
1 Introduction
Androgens are essential in the development and
maintenance of the prostate, and play an important role in the
malignant growth of the prostate. Flutamide is an antiandrogen and frequently used as therapeutic agent in
prostate cancer. Although flutamide therapy leads to the
elimination of androgen dependent prostate cancer cells,
it fails to arrest the androgen independent growth of cells.
The precise molecular switch underlying the
development of androgen independent prostate cancer (AIPC) is
poorly understood. However, possible mechanisms of
acquisition of an androgen independent state have been
proposed, including mutations in the ligand binding
regions of androgen receptor (AR), amplification of AR
and altered expression of AR coregulators [1]. The
emergence of AIPC has also been attributed to the multifocality
and heterogeneity of prostate tumors [2]. Various foci in
a tumor may vary in terms of their androgen dependence
and flutamide treatment may select the growth of
androgen independent foci. Lee et al. [3] demonstrate that
hydroxyflutamide (an active metabolite of flutamide) can
induce mitogen activated protein kinase (MAPK) cascade in AR negative DU145 cells, leading to enhanced
Cyclin D1 expression and cell proliferation. It was also
shown that these flutamide effects could be blocked by
an inhibitor or a neutralizing antibody against the
epidermal growth factor receptor. The data suggest the
possibility of AR independent effects of flutamide in prostate
cells and a direct role of flutamide in AIPC.
Interes-tingly, Wang et al. [4] showed that flutamide increases
the expression of the cell cycle related gene CDKN1A (a
cyclin dependent kinase inhibitor that blocks cell cycle
progression) in LNCaP prostate carcinoma cells. These
data taken together imply that flutamide exerts complex
cell type dependent effects on gene expression. Hence,
extensive studies on flutamide effects on gene
expression in the prostate cells are warranted.
Identification of androgen-regulated genes, especially
those that have roles in proliferation or apoptosis, has
the potential of offering alternative therapeutic targets.
Traditionally, a large number of androgen-regulated genes
have been identified using the rat castration model and
prostate cancer cell lines. However, very few studies
have used AR blockade with clinically used antiandrogens
such as flutamide or bicalutamide. Therefore, a
comprehensive knowledge of the effects of flutamide at the
level of gene expression in the prostate is lacking. In the
present study, we aimed at obtaining insights into the
effects of flutamide on gene expression using the rat
prostate model.
2 Materials and methods
2.1 Animals and hormonal manipulations
The present study used 60_70-day-old Wistar male
rats obtained from the Central Animal Facility at the
Indian Institute of Science. The rats were maintained
according to the institutional guidelines with access to rat
chow and water ad libitum. Orchidectomy was
performed under ether anesthesia, via the scrotal route and
maintained for 1, 3 or 5 days. Sham castrated rats
maintained for 5 days served as controls. Testosterone
propionate and 17β-estradiol (Sigma-Aldrich, St. Louis,
MO, USA) were given to day 2 castrated rats by daily
intra-peritonial injections of 1 mg/kg body weight in
propylene glycol as vehicle for 3 days. Flutamide
(Sigma-Aldrich, St. Louis, MO, USA) was given intraperitonially at a daily dose of 50 mg/kg body weight
in peanut oil (for differential display reverse transcriptase
polymerase chain reaction [DD-RT-PCR]) or 50 mg/kg
body weight in 100% DMSO once every 12 h for 5 days.
2.2 RNA extraction
RNA was extracted from frozen tissues using TRI
Reagent (Sigma-Aldrich, St. Louis, MO, USA) according to the manufacturer's instructions. The total RNA
was further purified using RNeasy Kit (Qiagen GmbH,
Hilden, Germany). RNA concentration was determined
by measuring the absorbance at 260 nm and the quality
assessed by agarose-formaldehyde gel electrophoresis.
2.3 DD-RT-PCR
The DD-RT-PCR protocol described by Wan and Erlander [5] was used with minor modifications.
Briefly, 500 ng of total RNA from the tissues was
reverse transcribed with anchored primer E1T12MT
(5'-CGGAATTCGGTTTTTTTTTTTTVT-3'; V = A, G or C) or E1T12MA
(5'-CGGAATTCGGTTTTTTTTTTTTVA-3'; V = A, G or C) in separate reactions. The
resultant cDNAs were diluted 20 times in water and
1 μL was used as template for PCR using 500 ng of anchor
primer (corresponding primer used during cDNA synthesis) and 500 ng of arbitrary primer AP2
(5'-CGTGAATTCGGACCGCTTGT-3') or AP3
(5'-CGTGAATTCGAGGTGACCGT-3') in the presence of
1 μCi of α-32P dCTP (3 000 Ci/mmole, Perkin Elmer Life
Sciences, Boston, MA, USA). The PCR conditions were
94ºC for 20 s, 42ºC for 20 s and 72ºC for 30 s for 40
cycles. Then, 1 μL of PCR product was mixed with
1 μL of sequencing loading dye (95% formamide, 10 mmol/L
EDTA, 0.1% xylene cyanol, 0.1% bromophenol blue), heated at 80ºC for 5 min, chilled on ice and resolved
in a 6% polyacrylamide gel containing 7 mol/L urea,
transferred into 3MM Whatman (3MM CHR) paper, dried under vacuum at 80ºC and exposed to an X-ray
film. The differentially expressed cDNAs were excised from the gel and transferred to
100 μL of water and the DNA was eluted by boiling for 15 min and
centrifugation at 10 621 × g for
5 min. The cDNA in the supernatant was reamplified using the same
combination of anchored and arbitrary primers and sequenced
in an automated sequencer (Applied Biosystems, Foster
City, CA, USA).
2.4 Semi-quantitative RT-PCR
Using a High Capacity cDNA Archive Kit (Applied
Biosystems, Foster City, CA, USA), 500 ng of total RNA
was reverse transcribed. cDNA equivalent to 10 ng of
total RNA was used as template for PCR reactions using
DyNAzyme II Master Mix (FINNZYMES, Espoo, Finland) with
1 μCi of α-32P dCTP (3 000 Ci/mmole,
Perkin Elmer Life Sciences, Boston, MA, USA) and gene
specific primers (Table 1) in a final volume of
20 μL. PCR reactions were carried out at cycle numbers in the
linear range of product amplification. 5 μL of the PCR
products were analyzed on 6% non-denaturing PAGE in
1 × TBE buffer. The gels were dried at 80ºC under
vacuum and exposed to X-ray films.
2.5 Northern blot analysis of b2-microglobulin
Using a Random Primer Labeling Kit (Bangalore Genei, Bangalore, Karnataka, India)
25 ng of β2-microglobulin cDNA (reamplified F1 fragment) was
labeled with α-32 P dCTP (specific activity 3 000 Ci/mmole,
Perkin Elmer, Boston, MA, USA), and purified using
Sephadex-G50 spin columns. Then,
15 μg of RNA was resolved on 1% agarose-formaldehyde gel and blotted
onto a nylon membrane (Biodyne B Membrane; Pall Corporation, East Hills, NY, USA). Prehybridization,
hybridization and washing steps were performed as
described previously [6].
2.6 Western blotting
Rabbit anti-β2m antibody (used in 1 : 2 500 dilution)
was a kind gift from Dr C.R. Wang (Department of Pathology, University of Chicago, USA).
Anti-β actin monoclonal antibody was from Sigma-Aldrich (St. Loius,
MO, USA) and horseradish peroxidase (HRP)-tagged goat
anti-rabbit and goat anti-mouse IgGs were from Santa
Cruz Biotechnology Inc. (Santa Cruz, CA, USA).
Tissues were homogenized in RIPA lysis buffer. The
supernatants were stored in _70ºC in small aliquots.
50 μg protein was resolved in a 10% denaturing SDS-PAGE
followed by electrophoretic transfer to Immobilon-P
membrane (Millipore Corporation, Bedford, MA, USA).
The membrane was blocked in 5% skimmed milk, incubated with primary antibody for 1 h, and washed and
incubated with appropriate secondary antibody for 1 h.
The blots were washed again and the HRP tagged secondary antibody was detected using Enhanced
Chemiluminescence plus Western Blotting Detection System
(Amersham Biosciences, Uppsala, Sweden) followed by exposure to X-ray films (Kodak, Rochester, NY,
USA).
3 Results
3.1 Identification of flutamide regulated genes by
DD-RT-PCR
To identify genes regulated upon androgen receptor
blockade in the rat ventral prostate, DD-RT-PCR was
performed with total RNA isolated from ventral
prostates of vehicle treated and flutamide-treated rats. Using
combinations of two anchored primers and two arbitrary primers, several differentially expressed fragments
were identified. Among several flutamide regulated
transcripts, we chose eight (F1_F8) for further analysis
(Figure 1 and Table 2). The sequences of these fragments
were used to search for homologies with the existing
sequences in the NCBI database using BLAST and their
identities are shown in Table 2. F3 and F5 transcript
sequences did not produce any significant hits. F8 was
identified as spermine binding protein (SBP), which is a
known androgen induced gene in the ventral prostate [7],
suggesting at the outset, the reliability of our
DD-RT-PCR protocol. Others showed identities to cytoplasmic
FMR1 interacting protein 2 (CYFIP2), pumilio 1
(Pum1), ribophorin II (RibII) and b2-microglobulin
(β2m) (Table 2).
3.2 β2m is an androgen repressed gene
Using Northern and Western blotting we studied
the effects of flutamide and castration on the
expression of β2m. As shown in Figure 2, castration induced
β2m mRNA gradually from day 1 to day 5
post-castra-tion. Compared to sham castrated controls, there was
a 6.03 ± 0.48-fold induction of β2m mRNA at day 3
and 11.62 ± 0.46-fold induction of
β2m mRNA at day 5 post-castration (mean
± SEM, n = 2). Testosterone supplementation reversed the effects of castration on the
expression of β2m mRNA (Figure 2A). Flutamide
treatment caused a 3.77 ± 0.42-fold induction of
β2m mRNA over the control (mean ± SEM,
n = 2) (Figure 2B), which was lesser in extent compared to that observed in day 5
castrated animals. Induction of β2m protein expression
by castration, as analyzed by western blotting,
correlated with the induction of mRNA and was reversed by
testosterone supplementation. The induction of β2m
protein over control was also observed upon flutamide
treatment, albeit to a lesser extent compared to
castration (Figure 2C).
3.3 Regulation of CYFIP2, Pum1 and RibII by
castration and flutamide
We compared the effect of flutamide and castration
on CYFIP2, Pum1 and RibII mRNA expressions using semiquantitative RT-PCR. As expected, both flutamide
and castration caused downregulation of prostatein C1
mRNA (Figure 3). Flutamide induced the steady-state
levels of CYFIP2 and Pum1 mRNAs but downregulated the levels of RibII mRNA (Figure 3). Therefore, the
results are in agreement with our DD-RT-PCR analysis.
Castration induced CYFIP2 and downregulated RibII mRNA expressions, in a manner similar to the effect of
flutamide treatment. Interestingly, although flutamide
induced the levels of Pum1 mRNA, castration had no
effect (Figure 3). The induction and downregulation of
CYFIP2 and RibII mRNAs, respectively, by castration
were also reversed by testosterone but not by estrogen
supplementation (Figure 3).
4 Discussion
The emergence of an androgen independent state is
a major hurdle in the effective treatment of prostate
cancer. Although it is likely that flutamide treatment
selects the AIPC cells, we hypothesized that flutamide might
also have a direct role in the emergence of an androgen
independent state. Our hypothesis is largely based on
the demonstration by Lee et al. [3] that hydroxyflutamide
can induce the MAPK pathway in AR negative cells.
Comprehensive studies on the effects of flutamide on
prostate cells are, therefore, relevant in this context. The
present work offers insights into the effects of flutamide
at the level of gene expression on prostate cells by way
of identifying novel flutamide regulated genes in the rat
ventral prostate using DD-RT-PCR. To our knowledge,
this is the first attempt to identify novel flutamide
regulated genes.
We have shown for the first time that androgen
represses the expression of β2m mRNA and protein in the
rat ventral prostate. The physiological relevance of
induction of β2m expression in the rat ventral prostate
post-castration is currently not clear. β2m has been shown
to exert a mitogenic effect on PC3 cells by antagonizing
TGF-b1 action [8]. Hence, the significance of induction
of β2m in the context of castration induced expression
of TGF-b1 concomitant to prostate epithelial cell death
[6, 9] needs to be addressed. Increased expression of
major histocompatibility class 1 (MHC I)/β2m and soluble
β2m in tissue fluids is an established phenomenon in
cases of viral infection and tissue degeneration [10, 11].
The increased cell surface expression of MHC I/β2m
leads to stimulation of T cell response and cytolytic
activity to eliminate degenerating cells. The increased
soluble β2m might function to induce proliferation of
adjacent non-degenerating cells as a part of the tissue
repair process. In a microarray study to identify
androgen regulated genes in the rat ventral prostate, MHC
I antigen gene was identified as an androgen repressed
gene [12]. Infiltration of immune cells in the rat
ventral prostate following castration is also known [13].
Therefore, induction of MHC I/β2m in the rat ventral
prostate could signal cytotoxic T cells to eliminate
degenerating cells of the prostate following castration.
β2m has been shown to induce proliferation of PS-1
prostate stromal cells [8]. The induced β2m
following castration is likely to influence the proliferation of
prostatic stromal cells or adjacent basal epithelial cells,
which remain unaffected by castration.
CYFIP2 plays a role in development and maintenance
of dendritic spines and neuronal plasticity and is involved
in fragile X mental retardation syndrome [14]. The
significance of CYFIP2 mRNA induction in the rat ventral
prostate upon castration or flutamide treatment is
certainly not obvious. Investigations into the expression
and androgen regulation of its interacting proteins, such
as FMRP, FXR1 and FXR2, might provide clues into the
possible roles of these proteins in normal or involuting
rat ventral prostate. Interestingly, FMRP is known to be
associated with actively translating ribosomes [15]. In
addition, recent data indicates that FMRP might inhibit
translation of mRNA [16]. Being an interacting partner
of FMRP, CYFIP2 might be involved in the translational
shut-off of a wide array of secretory proteins expressed
in the prostate epithelium following castration and
flutamide treatments. Induction of p53 has been shown
in the rat ventral prostate following castration [17].
Interestingly, CYFIP2 is known to be a p53 inducible
protein [18]. It is possible that CYFIP2 might have a
role in castration-induced cell death of the prostate
epithelium.
Pum1 is a member of an evolutionarily conserved
PUF (for Pumilio and FBF) family of RNA binding
proteins [19]. In drosophila, the Pum is involved in
translational repression of maternal hunchback mRNA, which
is necessary for proper posterior segmentation and
abdomen formation. It represents a well-characterized
model of translational repression [20]. Our data
suggests induction of Pum1 by flutamide. It is likely that
Pum1 is involved in translational repression of target
mRNAs in the rat ventral prostate and is a subject of
future investigations.
For secretory epithelial cells, such as the ones present
in the prostate, the cellular processes involved in protein
synthesis, processing, trafficking and secretion will be
highly active. Because the differentiated function of the
prostate is androgen dependent, it follows that these
cellular activities and participating molecules therein will be
androgen dependent. We show RibII as an androgen regulated gene in the rat ventral prostate. RibII is a
component of the oligosaccharyl transferase, which is
involved in transfer of high mannose oligosaccharide to
the nascent polypeptide chains and, therefore, has a role
in protein processing. DAD1, which is also a
component of the oligosaccharyl transferase has been shown
to be androgen induced in the rat ventral prostate [12].
Taken together, these data suggest the androgen
dependence of the expression of the oligosaccharyl transferase
complex in prostate cells and a role for androgen in
protein glycosylation.
We have demonstrated that castration and flutamide
treatments cause differential effects. In the present study,
three distinct patterns of differential modulation of gene
expression hitherto unreported in the published literature
have been observed: (i) dowregulation by both
castration and flutamide treatments (RibII); (ii) upregulation
by both castration and flutamide treatments (β2m, CYFIP2); and (iii) upregulation by flutamide but not by
castration (Pum1). The similar and differential patterns
of modulation of gene expression are suggestive of the
following possibilities. First, the observed regulation of
a given gene following castration need not necessarily be
a result of androgen ablation. Instead, it could be a
consequence of enrichment of stromal cells following
castration. Alternatively, it could represent secondary
effects of cell death. Second, actions of androgen at the
level of gene expression could be mediated via
mechanisms independent of the canonical AR. We have shown
that β2m is induced by both castration and flutamide
treatments. However, the level of induction by flutamide
is only partial (compared to castration). Because
flutamide does not cause apoptosis of the prostate
epithelium it is likely that the greater induction of
β2m by castration compared to flutamide could be a combined
effect of loss of androgen signaling and
castration-induced cell death. Finally, regulation of Pum1 by
flutamide alone suggests that flutamide might have
independent effects on gene expression.
Therefore, we propose that interpretation of genes
as "androgen regulated" based solely on the effects of
castration and testosterone reversal could be misleading.
This has a lot of bearing with regards to the search for
novel androgen regulated genes as therapeutic targets
for prostate cancer. Our data also suggest that flutamide
might have independent effects on the level of gene
expression. Such independent actions of flutamide
could impact tremendously on the outcomes of antiandrogen therapy of prostate cancer. Further
investigation might help in better understanding the
failure of flutamide therapy and its role in androgen
independence. Detailed studies on the regulation,
function and upstream and downstream targets of novel
genes identified in the present study might provide
valuable insights into mechanisms by which androgens
control various cellular processes.
Acknowledgment
We thank Dr C. R. Wang (Department of Pathology,
University of Chicago) and Dr D. Nandi (IISc Bangalore)
for anti-β2m antibodies and the staff of the central
animal facility at IISc for providing animals. This work
was funded by the Department of Biotechnology, Go-vernment of India. Infrastructure support from the
Department of Science and Technology, Indian Council of
Medical Research and University Grants Commission,
India is acknowledged.
References
1 Feldman BJ, Feldman D. The development of androgen
independent prostate cancer. Nat Rev Cancer 2001; 1: 34_45.
2 Griffiths K, Eaton CL, Davies P. Prostatic cancer: aetiology
and endocrinology. Horm Res 1989; 32 Suppl 1: 38_43.
3 Lee YF, Lin WJ, Huang J, Messing EM, Chan FL, Wilding G,
et al. Activation of mitogen-activated protein kinase pathway
by the antiandrogen hydroxyflutamide in androgen
receptor-negative prostate cancer cells. Cancer Res 2002; 62: 6039_44.
4 Wang Y, Shao C, Shi CH, Zhang L, Yue HH, Wang PF,
et al. Change of the cell cycle after flutamide treatment in prostate
cancer cells and its molecular mechanism. Asian J Androl 2005;
7: 375_80.
5 Wan JS, Erlander MG. Cloning differentially expressed genes
by using differential display and subtractive hybridization.
Methods Mol Biol 1997; 85: 45_68.
6 Desai KV, Kondaiah P. Androgen ablation results in
differential regulation of transforming growth factor-beta isoforms in
rat male accessory sex organs and epididymis. J Mol Endocrinol
2000; 24: 253_60.
7 Chang CS, Saltzman AG, Hiipakka RA, Huang IY, Liao SS.
Prostatic spermine-binding protein. Cloning and nucleotide
sequence of cDNA, amino acid sequence, and androgenic
control of mRNA level. J Biol Chem 1987; 262: 2826_31.
8 Rowley DR, Dang TD, McBride L, Gerdes MJ, Lu B, Larsen
M. Beta-2 microglobulin is mitogenic to PC-3 prostatic
carcinoma cells and antagonistic to transforming growth factor beta
1 action. Cancer Res 1995; 55: 781_6.
9 Kyprianou N, Isaacs JT. Expression of transforming growth
factor-beta in the rat ventral prostate during
castration-induced programmed cell death. Mol Endocrinol 1989; 3:
1515_22.
10 Griffin DE, Ward BJ, Jauregui E, Johnson RT, Vaisberg A.
Immune activation in measles. N Engl J Med 1989; 320:
1667_72.
11 Mehta PD, Kulczycki J, Mehta SP, Sobczyk W, Coyle PK,
Sersen EA, et al. Increased levels of beta 2-microglobulin,
soluble interleukin-2 receptor, and soluble CD8 in patients
with subacute sclerosing panencephalitis. Clin Immunol
Immunopathol 1992; 65: 53_9.
12 Jiang F, Wang Z. Identification of androgen responsive genes
in the rat ventral prostate by complementary deoxyribonucleic
acid subtraction and microarray. Endocrinology 2003; 144:
1257_65.
13 Desai KV, Michalowska AM, Kondaiah P, Ward JM, Shih
JH, Green JE. Gene expression profiling identifies a unique
androgen mediated inflammatory/immune signature and a PTEN
(phosphatase and tensin homolog deleted on chromosome
10)-mediated apoptotic response specific to the rat ventral
prostate. Mol Endocrinol 2004; 18: 2895_907.
14 Comery TA, Harris JB, Willems PJ, Oostra BA, Irwin SA,
Weiler IJ, et al. Abnormal dendritic spines in fragile X
knockout mice: maturation and pruning deficits. Proc Natl Acad Sci
U S A 1997; 94: 5401_4.
15 Corbin F, Bouillon M, Fortin A, Morin S, Rousseau F,
Khandjian EW. The fragile X mental retardation protein is
associated with poly(A)+ mRNA in actively translating
polyribosomes. Hum Mol Genet 1997; 6: 1465_72.
16 Laggerbauer B, Ostareck D, Keidel EM, Ostareck-Lederer A,
Fischer U. Evidence that fragile X mental retardation protein
is a negative regulator of translation. Hum Mol Genet 2001;
10: 329_38.
17 Zhang X, Colombel M, Raffo A, Buttyan R. Enhanced
expression of p53 mRNA and protein in the regressing rat ventral
prostate gland. Biochem Biophys Res Commun 1994; 198:
1189_94.
18 Saller E, Tom E, Brunori M, Otter M, Estreicher A, Mack DH,
et al. Increased apoptosis induction by 121F mutant p53.
EMBO J 1999; 18:4424_37.
19 Spassov DS, Jurecic R. The PUF family of RNA-binding
proteins: does evolutionarily conserved structure equal
conserved function? IUBMB Life 2003; 55: 359_66.
20 Sonoda J, Wharton RP. Recruitment of Nanos to hunchback
mRNA by Pumilio. Genes Dev 1999; 13:2704_12.
|